Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Peking University Third Hospital maintains 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 3 distinct examiners and 3 distinct art units. HAGHIGHATIAN, MINA is the busiest examiner, currently handling 1 pending office action.
This distribution suggests that each of the 3 pending office actions is being evaluated in a unique technical context. Practitioners should be prepared for 3 distinct examination paths within the biotechnology sector, as each case is assigned to a different examiner and art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAGHIGHATIAN, MINA | 1 | 46.0% | +39.4% |
| GREENE, IVAN A | 1 | 18.8% | +6.1% |
| KWON, YONG SOK | 1 | 24.6% | +42.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18932725 | TISSUE-DERIVED IMPLANT USEFUL FOR CARTILAGE REGENERATION | HAGHIGHATIAN, MINA | — |
| 18743948 | ANTI-TUMOR PHARMACEUTICAL COMPOSITION COMPRISING EZH2 INHIBITOR AND SCD1 INHIBITOR AND USE THEREOF | GREENE, IVAN A | — |
| 18701160 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTI-TUMOR EFFECT OF EZH2 INHIBITOR AND USE THEREOF | KWON, YONG SOK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18932725 | TISSUE-DERIVED IMPLANT USEFUL FOR CARTILAGE REGENERATION | HAGHIGHATIAN, MINA | — |
| 18701160 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTI-TUMOR EFFECT OF EZH2 INHIBITOR AND USE THEREOF | KWON, YONG SOK | — |
| Art Unit | Apps |
|---|---|
| 1616 | 1 |
| 1619 | 1 |
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18932725 | TISSUE-DERIVED IMPLANT USEFUL FOR CARTILAGE REGENERATION | HAGHIGHATIAN, MINA | 1616 | §103§112 | Non-Final OA | — | Pending | Oct 31, 2024 |
| 18743948 | ANTI-TUMOR PHARMACEUTICAL COMPOSITION COMPRISING EZH2 INHIBITOR AND SCD1 INHIBITOR AND USE THEREOF | GREENE, IVAN A | 1619 | §103§112 | Non-Final OA | — | Pending | Jun 14, 2024 |
| 18701160 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTI-TUMOR EFFECT OF EZH2 INHIBITOR AND USE THEREOF | KWON, YONG SOK | 1613 | §103§112 | Non-Final OA | — | Pending | Apr 12, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPeking University Third Hospital has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Mina Haghighatian has the most, with 1 of Peking University Third Hospital's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
